Reader’s guide · First edition · September 2026 · Revised October 1, 2026
BPC-157
A guide to the healing peptide: a thousand animal studies, thirty human subjects, and a rule change in progress
BPC-157 is a 15-amino-acid fragment of a protein found in human gastric juice. In rats it speeds the healing of cut tendons, torn muscles, and injured gut lining, which is why it has become the most talked-about peptide in sports and wellness clinics. In people it has been studied in about thirty patients, never against a placebo. This guide separates what the animal work shows from what is known in humans, and explains where the FDA stands after a year of rule changes.
Who this is for
Written for adults who are using, or being offered, BPC-157 for an injury, gut problem, or general recovery. It summarizes the published record and the regulatory position as of the edition date. It is not medical advice.
BPC-157 ("body protection compound") is a synthetic pentadecapeptide, a chain of fifteen amino acids copied from part of a larger protein in gastric juice. It was isolated in the 1990s by a research group in Zagreb, which has produced nearly all of the studies on it since. Unlike most peptides it survives stomach acid, so it is used by mouth as well as by injection.
- Class
- Synthetic pentadecapeptide; not a hormone or hormone analog
- Forms in use
- Subcutaneous injection (reconstituted from powder), oral capsules, intra-articular injection in clinics
- Status
- Not approved anywhere. Not on FDA's 503A bulk-substances list, so not lawfully compoundable, as of this edition. An FDA advisory committee recommended adding it in July 2026; rulemaking is pending.
- Anti-doping
- Prohibited by WADA at all times since 2022 (S0, non-approved substances)
- Maker
- None. No company holds an approval or is running a registered trial.
Popular is not the same as proven
The gap between BPC-157's reputation and its evidence is unusually wide. Over five hundred papers describe it, almost all in rodents and almost all from one laboratory. The published human record is three small uncontrolled studies. Section 03 lists every one.
In rats and mice, BPC-157 has been reported to accelerate healing across an improbable range of tissues. The proposed mechanisms are new blood-vessel growth (angiogenesis), modulation of the nitric-oxide system, and activation of growth-factor signaling in fibroblasts and tendon cells.
| Model | Reported effect in rodents | Human relevance |
|---|---|---|
| Cut Achilles tendon, torn quadriceps, transected ligament | Faster reattachment and load tolerance; more fibroblast outgrowth | Untested in people |
| Stomach and bowel injury, NSAID and alcohol damage | Smaller ulcers; protection from drug toxicity | Untested in people |
| Blood vessels | New vessel formation; recovery after vessel occlusion | The same pathway that tumors use; a stated concern |
| Nerve and spinal-cord injury, brain lesions | Functional recovery | Untested in people |
| Wound healing, burns, fistulas | Faster closure | Untested in people |
Doses in these studies are usually 10 micrograms per kilogram or higher, given by injection or in drinking water, in animals with surgically created injuries. Independent replication outside the originating group is limited.
Animal results of this breadth are not a reason to dismiss the peptide, but they are not evidence that it works in people. Many compounds that heal rat tendons have failed in human trials, and BPC-157 has never been put through one.
Total people studied across those reports
Randomized, placebo-controlled trials completed for any use
Registered trials actively recruiting (a 2015 Phase 1 study was withdrawn before enrolling)
| Year | Study | Result | Control group |
|---|---|---|---|
| 2021 | 16 patients, BPC-157 injected into painful knees, some with thymosin beta-4 | 14 of 16 reported relief at 6 to 12 months | None |
| 2024 | 12 patients with interstitial cystitis, 10 mg instilled into the bladder | 10 of 12 reported complete symptom resolution | None |
| 2025 | 2 healthy adults, 10 mg then 20 mg by intravenous infusion | No adverse effects; blood levels back to baseline within 24 hours | None |
Uncontrolled case series cannot separate a drug's effect from placebo, natural recovery, or the injection itself. They are hypothesis-generating, not proof.
What would count as evidence
A randomized trial against placebo or standard care in a defined injury, with a pre-registered outcome and independent funding. None exists, and as of this edition none is registered.
Clinics and sellers have converged on protocols by custom, not by dose-finding studies. None of the doses below has been shown to do anything in a controlled human trial, and until the 2025 infusion pilot no one had measured BPC-157 levels in human blood at all.
| Route | Typical instruction | What is known |
|---|---|---|
| Subcutaneous injection | 200 to 500 micrograms once or twice daily, often near the injury, for 2 to 6 weeks | No human dose-response data |
| Oral capsule | 250 to 500 micrograms daily | Survives gastric acid in animals; human absorption unmeasured |
| Intra-articular injection | Single or repeated injections into a joint by a clinician | One 16-patient case series |
| Combined with TB-500 | Stacked with thymosin beta-4 fragment | No study of the combination |
What the next table is, and is not
It expresses the common clinic protocol for the vial size sold, so the arithmetic can be checked. Nothing in it has been validated in a controlled trial, BPC-157 is not yet lawfully compoundable, and a research-chemical vial's stated strength is unverified.
- Vial
- 10 mg, as sold; identity and quantity unverified unless a pharmacy dispensed it
- Water added
- 4 mL bacteriostatic water, if the vial holds it (most 10 mg vials are 3 or 5 mL glass). A 2 mL vial takes 2 mL, which doubles the concentration and halves every unit figure below.
- Concentration
- 2,500 mcg/mL with 4 mL (5,000 mcg/mL with 2 mL). One concentration for the whole course.
- Syringe
- 0.3 mL insulin syringe with half-unit marks for draws under 30 units; 1 mL syringe above that
| Weeks | Daily dose | Draw | Units | Used per 4 weeks |
|---|---|---|---|---|
| 1–2 | 250 mcg | 0.1 mL | 10 | 7 mg (1 vial) |
| 3–6 | 500 mcg, or 250 mcg twice daily | 0.2 mL | 20 | 14 mg (2 vials) |
| After 6 | Stop and reassess |
There is no escalation in the literature; this is custom. With 2 mL of water instead of 4, the draws are 5 and 10 units, and a 5-unit draw is too small to measure accurately.
What each draw looks like · 0.5 mL (50-unit) U-100 insulin syringe
The plunger tip sits on the line for the dose. Units are marks on a U-100 syringe: 100 units is 1 mL. The picture assumes the concentration in the table above; a different amount of water changes every line.
- "Near the injury" has no established rationale for a peptide that enters the bloodstream; the animal studies mostly dosed systemically.
- Duration, cycling, and dose escalation are borrowed from bodybuilding forums, not from pharmacology.
- Oral and injected forms are treated as interchangeable by sellers. In people, nobody knows.
BPC-157 has never been submitted for approval. The live question is narrower: whether pharmacies may compound it. That turns on FDA's list of bulk substances allowed under section 503A, and the answer has changed twice in three years.
| Date | Event |
|---|---|
| 2015 | A Phase 1 trial is registered, then withdrawn without enrolling |
| 2022 | WADA adds BPC-157 to the Prohibited List as a non-approved substance |
| Sep 2023 | FDA places BPC-157 in Category 2 of the 503A bulks list, citing immunogenicity and impurity concerns: not to be compounded |
| 2025 | FDA warning letters to sellers marketing BPC-157 for healing and performance |
| Apr 2026 | BPC-157 and eleven other peptides removed from Category 2 after their nominations were withdrawn |
| Jul 2026 | FDA's Pharmacy Compounding Advisory Committee votes 8 to 6, with one abstention, to recommend adding BPC-157 to the 503A list |
| Next | FDA rulemaking, typically six to twelve months. Until it completes, the substance is not on the list |
As of this edition, still not compoundable
Leaving Category 2 did not make BPC-157 eligible; it made it eligible for consideration. The advisory vote is a recommendation, not a rule. A pharmacy compounding BPC-157 today is doing so without a legal basis, and the vials sold online come from chemical suppliers with no pharmacy involved at all.
- If FDA adds BPC-157 to the 503A list, licensed pharmacies could compound it on a prescription. That would not make it approved, tested for effectiveness, or covered by insurance.
- FDA's 2023 safety concern was about the product, not the molecule: unverified purity, peptide-related impurities, and the immune response they can provoke. Those concerns apply with full force to research-chemical vials.
- "Research use only" labels are cover for the seller. FDA's 2025 letters were to companies selling exactly those products with dosing instructions.
Reading a vial: the microgram arithmetic9
People are injecting BPC-157 now, from powder they reconstitute themselves. The dosing is in micrograms, the vials are labeled in milligrams, and the syringes are marked in units. That is three unit systems in one step, and a thousandfold error is one decimal point away.
units = (dose mcg ÷ concentration mcg/mL) × 100
A 10 mg vial (10,000 mcg) reconstituted with 4 mL of bacteriostatic water is 2,500 mcg/mL. A 250 mcg dose is 0.1 mL, which is 10 units on a U-100 insulin syringe.
| Water added | Concentration | 250 mcg | 500 mcg |
|---|---|---|---|
| 2 mL | 5,000 mcg/mL | 5 units (0.05 mL) | 10 units (0.1 mL) |
| 4 mL | 2,500 mcg/mL | 10 units (0.1 mL) | 20 units (0.2 mL) |
| 5 mL | 2,000 mcg/mL | 12.5 units (0.125 mL) | 25 units (0.25 mL) |
Reconstituted peptide is a multi-dose vial with no tested beyond-use date. Refrigerate, and assume it degrades within weeks.
The honest summary is that BPC-157 has not been shown to be dangerous, and has not been shown to be safe, because the studies that would show either have not been done.
- Reported
- No serious adverse events in the three small human studies. Anecdotally: injection-site irritation, nausea, dizziness, fatigue.
- Theoretical
- It promotes new blood-vessel growth, a pathway tumors depend on. No study has examined use in people with cancer or a cancer history.
- Product
- FDA's stated concern: immunogenicity and impurities. Peptide synthesis leaves truncated and modified chains that can provoke immune reactions.
- Sterility
- Research-chemical vials are not certified sterile or endotoxin-free for injection.
- Unknown
- Effects in pregnancy, in adolescents, with other medicines, and beyond a few weeks of use.
- Athletes
- A positive anti-doping test at any time, including out of competition. Contaminated supplements have caused unintended positives.
- Is BPC-157 FDA-approved for anything? (No.)
- Is it on FDA's 503A compounding list yet? Which pharmacy made this, and under what authority?
- What is the human evidence for my specific injury or condition? Can you show me the study?
- What is the concentration, who tested it, and can I see the certificate of analysis for this batch?
- How was it reconstituted, when, and what is the beyond-use date?
- Am I subject to anti-doping rules, at work or in sport?
- What proven treatment for this injury am I delaying or skipping?
- If it does nothing in six weeks, what is the plan?
What does have evidence for tendon and ligament injury
Progressive loading under a physical therapist, sleep and protein sufficiency, and time. Less glamorous than a peptide, and the only things shown to work in controlled human trials.
Latest
Developments since this edition, newest first. Items here are dated and sourced; they update the guide without re-editing it.
WADA's 2027 list keeps BPC-157 prohibited at all times
The 2027 Prohibited List, in force January 1, 2027, leaves BPC-157 under S0 as a substance with no regulatory approval anywhere. The headline changes this year concern cannabinoids.
UCLA review of 565 studies finds almost no human evidence for six popular recovery peptides
Orthopedic researchers reviewed 565 studies of BPC-157, TB-500, CJC-1295, ipamorelin, MK-677, and GHK-Cu for muscle, tendon, and joint use (American Journal of Sports Medicine, 2026). More than two-thirds were animal-only, and the authors found essentially no studies showing a significant clinical benefit for musculoskeletal conditions.
Hims & Hers preparing BPC-157 for compounding, pending FDA action
The company is stability-testing BPC-157 for its pharmacy contingent on FDA finishing rulemaking after the July vote, which analysts expect to take about a year.
Law firm: the vote changed no law and no proposed rule has appeared
Only notice-and-comment rulemaking or an act of Congress can add BPC-157 to the 503A list; as of this note FDA had issued no proposal. That remains true at the time of this update.
Advisory committee votes 8 to 6, one abstaining, to recommend listing
The committee recommended BPC-157 for ulcerative colitis over FDA staff objections about the absence of human data. The recommendation is nonbinding.
References
- 1.Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632.
- 2.Józwiak M, et al. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals. 2025;18(2):185. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11859134/
- 3.Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. 2025. PMC12446177. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
- 4.Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. https://pubmed.ncbi.nlm.nih.gov/34324435/
- 5.Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024.
- 6.Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025.
- 7.U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee, July 23-24, 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 8.AJMC. FDA panel backs 6 peptides for compounding. July 2026. https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
- 9.U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (Category 2 placement, September 2023; removal, April 2026). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act
- 10.U.S. Anti-Doping Agency. BPC-157: experimental peptide creates risk for athletes. https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
- 11.STAT News. BPC-157: the peptide with big claims and scant evidence. February 3, 2026. https://www.statnews.com/2026/02/03/bpc-157-peptide-science-safety-regulatory-questions/
- 12.World Anti-Doping Agency. The Prohibited List: S0, non-approved substances. Current edition.